Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2014

View Archived Issues

Merck Research Laboratories describes discovery of potent HCV NS5B polymerase inhibitor prodrug

Domestic pesticide shows efficacy and safety for the treatment of INS

Early clinical and preclinical data presented for DS-5565

Shionogi presents highlights of fiscal 2013

Allecra Therapeutics reports on new potent beta-lactamase inhibitor

Chinese investigators test novel CLK1 inhibitors as anti-influenza agents

NOX4, a novel biomarker for non-valvular atrial fibrillation

Catabasis Pharmaceuticals presents preclinical data for CAT-2003

Aquilus Pharmaceuticals patents new MMP-13 inhibitors

Almirall divulges novel PI3Kdelta inhibitors

Calibr receives Gates Foundation research funding

Merck & Co. divulges new agents for HCV infection

Servier and Novartis enter into agreement for new drugs targeting apoptosis in oncology

Icahn School of Medicine awarded grant to investigate new therapy for eczema

Revive Therapeutics reports preclinical data for REV-003

BMS and Celldex Therapeutics to evaluate the combination of nivolumab and varlilumab

Daewoong Pharmaceutical synthesizes novel Na(V)1.7 blockers

Ono Pharmaceutical recaps progress of fourth quarter of fiscal 2013

Questcor licenses melanocortin peptides

Alexion studies ALXN-1007 for non-criteria manifestations of antiphospholipid syndrome

FDA grants nivolumab breakthrough therapy designation for Hodgkin's lymphoma

Novartis plans phase I/II study of CGF-166

Helix BioPharma seeks Canadian clearance for study of L-DOS47

ValiSeek reports encouraging results for VAL-401 development

Eisai resubmits additional benefit dossier for Fycompa in Germany

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...